Table 3. Relative Risk of Death After... | American Society of Hematology

Table 3.

Relative Risk of Death After HLA-Identical Sibling Bone Marrow Transplantations for Severe Aplastic Anemia Between 1976 and 1992

Variable	No Adjustment		Adjusted for Patient and Disease-Related Variables		Adjusted for Patient-,
	Relative Risk	95% CI	Relative Risk	95% CI	Disease-, and Transplant-
					Related Variables
					Relative Risk	95% CI
Year of transplant
1976-1980	1.00^3-150	—	1.00^3-150	—	1.00^3-150	—
1981-1987 (≤3 mo)	0.53^3-151	0.40-0.71	0.55^3-151	0.41-0.73	0.70^3-152	0.52-0.95
1988-1992 (≤3 mo)	0.25^3-151	0.18-0.36	0.25^3-151	0.18-0.36	0.42^3-151	0.27-0.65
1981-1987 (>3 mo)	0.91	0.60-1.36	0.93	0.62-1.40	1.16	0.76-1.76
1988-1992 (>3 mo)	1.08	0.71-1.66	1.04	0.68-1.59	1.68^3-152	1.03-2.74
Increasing age (per yr of age)			1.02^3-151	1.02-1.03	1.02^3-151	1.01-1.03
>20 Transfusions (v ≤20 transfusion)			1.58^3-151	1.29-1.92	1.65^3-151	1.35-2.02
Prior treatment (v no prior treatment)			—	NS	—	NS
Time to transplant >2 mo (v ≤2 mo)			1.36^3-151	1.04-1.76	1.35^3-152	1.04-1.75
Neutrophils <0.2 × 10⁹/L (v ≥0.2 × 10⁹/L)			—	NS	—	NS
Donor-recipient sex-mismatch (v sex-match)					1.29ρ	1.08-1.54
Cell dose ≥3 × 10⁸/kg (v <3 × 10⁸/kg)					—	NS
Buffy coat cells (v no buffy coat cells)					1.25^3-152	1.02-1.54
Conditioning regimen^3-154					—	NS
GVHD prophylaxis
MTX + CSA					1.00	—
CSA					1.19	0.91-1.56
MTX					1.71^3-155	1.25-2.34
T-cell depletion					0.86	0.45-1.66
Other^3-167					4.16^3-151	2.38-7.28

Variable	No Adjustment		Adjusted for Patient and Disease-Related Variables		Adjusted for Patient-,
	Relative Risk	95% CI	Relative Risk	95% CI	Disease-, and Transplant-
					Related Variables
					Relative Risk	95% CI
Year of transplant
1976-1980	1.00^3-150	—	1.00^3-150	—	1.00^3-150	—
1981-1987 (≤3 mo)	0.53^3-151	0.40-0.71	0.55^3-151	0.41-0.73	0.70^3-152	0.52-0.95
1988-1992 (≤3 mo)	0.25^3-151	0.18-0.36	0.25^3-151	0.18-0.36	0.42^3-151	0.27-0.65
1981-1987 (>3 mo)	0.91	0.60-1.36	0.93	0.62-1.40	1.16	0.76-1.76
1988-1992 (>3 mo)	1.08	0.71-1.66	1.04	0.68-1.59	1.68^3-152	1.03-2.74
Increasing age (per yr of age)			1.02^3-151	1.02-1.03	1.02^3-151	1.01-1.03
>20 Transfusions (v ≤20 transfusion)			1.58^3-151	1.29-1.92	1.65^3-151	1.35-2.02
Prior treatment (v no prior treatment)			—	NS	—	NS
Time to transplant >2 mo (v ≤2 mo)			1.36^3-151	1.04-1.76	1.35^3-152	1.04-1.75
Neutrophils <0.2 × 10⁹/L (v ≥0.2 × 10⁹/L)			—	NS	—	NS
Donor-recipient sex-mismatch (v sex-match)					1.29ρ	1.08-1.54
Cell dose ≥3 × 10⁸/kg (v <3 × 10⁸/kg)					—	NS
Buffy coat cells (v no buffy coat cells)					1.25^3-152	1.02-1.54
Conditioning regimen^3-154					—	NS
GVHD prophylaxis
MTX + CSA					1.00	—
CSA					1.19	0.91-1.56
MTX					1.71^3-155	1.25-2.34
T-cell depletion					0.86	0.45-1.66
Other^3-167					4.16^3-151	2.38-7.28

Abbreviations: CI, confidence interval; NS, not significant.

Baseline.

P < .0001.

P < .05.

ρ P < .01.

P < .001.

Categories considered: cyclophosphamide alone, Cy + ATG, Cy + TBI, Cy + LFR, and other.

Other means corticosteroids, no GVHD prophylaxis.